IBIO 100
Alternative Names: CFB-03; IBIO CFB03; IBIO-100Latest Information Update: 28 Jan 2024
At a glance
- Originator Medical University of South Carolina
- Developer iBio Inc; University of Texas Southwestern Medical Center
- Class Angiostatic proteins; Antifibrotics; Peptides; Recombinant proteins; Skin disorder therapies
- Mechanism of Action Angiogenesis inhibitors; Gelatinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
- No development reported Idiopathic pulmonary fibrosis; Systemic scleroderma
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for preclinical development in Idiopathic-pulmonary-fibrosis in USA (IV, Infusion)
- 28 Jan 2024 No recent reports of development identified for preclinical development in Idiopathic-pulmonary-fibrosis in USA (PO)
- 28 Jan 2024 No recent reports of development identified for preclinical development in Systemic-scleroderma in USA (IV, Infusion)